GlobeNewsWire·4d ago
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes– KO-7246 regenerated functional β - cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –
Kura Oncology's near-term viability hinges on converting its $464.4M deferred revenue balance into recognized income while managing a cash position of $70.2M against a quarterly operating loss of $73.0M. The company's 36.5% YoY revenue growth in 2026Q2 is enti...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.77+12.2% vs -$0.88 | $21M+3.5% vs $20M |
Q2 2026 May 12, 2026 | -$0.83+5.7% vs -$0.88 | $18M-29.7% vs $26M |
Q2 2026 Mar 5, 2026 | -$0.92-27.8% vs -$0.72 | $17M-51.1% vs $35M |
Q4 2025 Nov 4, 2025 | -$0.85-49.1% vs -$0.57 | $21M-59.7% vs $51M |
– KO-7246 regenerated functional β - cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –
Squarepoint Ops LLC lessened its stake in shares of Kura Oncology, Inc. (NASDAQ: KURA) by 88.5% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,171 shares of the company's stock after selling 78,432 shares during the quarter. Squarepoint Ops LLC's
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral presentation at European Association for the Study of Diabetes (EASD) Annual Meeting on September 29, 2026 – – Separately financed subsidiary provides dedicated capital and leadership to advance KO-7246 through initial clinical proof of concept while Kura retains a substantial ownership stake in Caspian, representing approximately half of the company on a fully diluted basis, and remains focused on oncology – SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the launch of Caspian Therapeutics, Inc. (“Caspian”), a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases.
Benchmark KURA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Kura Oncology, Inc. (KURA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.65 | $945.45M | -3.35 | 25.24% | -412.95% | -94.82% | — | |
| $3.58 | $227.56M | -3.03 | 0.78% | -8.7% | -31.27% | — | |
| $4.90 | $198.94M | 4.02 | 55.25% | 45.97% | 10.97% | — | |
| $31.80 | $1.89B | -4.47 | 48.03% | -418.24% | -35.67% | — | |
| $33.62 | $6.94B | -12.14 | — | -7585.86% | -69.59% | — | |
| $206.64 | $43.93B | -34.73 | — | — | -96.44% | — |
Kura Oncology, Inc. (KURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Kura Oncology, Inc. (KURA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jul 29, 2026·SEC
Jun 4, 2026·SEC
Get notified when KURA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Kura Oncology, Inc. (KURA) stock FAQ — growth, dividends, profitability & financials explained
Kura Oncology, Inc. (KURA) reported $77.2M in revenue for fiscal year 2025.
Kura Oncology, Inc. (KURA) grew revenue by 25.2% over the past year. This is strong growth.
Kura Oncology, Inc. (KURA) reported a net loss of $296.8M for fiscal year 2025.
Kura Oncology, Inc. (KURA) has a return on equity (ROE) of -94.8%. Negative ROE indicates the company is unprofitable.
Kura Oncology, Inc. (KURA) had negative free cash flow of $117.4M in fiscal year 2025, likely due to heavy capital investments.
